Enhanced navigation shortens time until guideline-adherent, postoperative radiotherapy (PORT) among patients with head and neck squamous cell carcinoma (HNSCC) compared with standard navigation, ...
Among patients with head and neck squamous cell carcinoma (HNSCC) undergoing chemoradiotherapy, higher baseline salivary Lachnoanaerobaculum abundance was associated with substantially improved ...
Phase I trial of the ATR inhibitor BAY 1895344 combined with stereotactic body radiation therapy and pembrolizumab for recurrent head and neck squamous cell carcinoma. Background: Definitive treatment ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Panelists discuss how recurrent metastatic head and neck squamous cell carcinoma (HNSCC) manifests through symptoms such as persistent sore throat and neck lumps, with risk factors including tobacco ...
The number of diagnosed incident cases of head and neck squamous cell carcinoma (HNSCC) are projected to climb from 229,000 cases in 2024 to 273,000 cases in 2034 across the eight major markets (8MM: ...
Spatial transcriptomics analysis to predict response to immune checkpoint blockade (ICB) in recurrent or metastatic head and neck squamous cell cancer (RM-HNSCC). ctDNA tumor fraction (TF) to predict ...
Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap. Company now e ...
Zacks Investment Research on MSN
NTRA & Aveta partner to advance MRD-guided trial in head & neck cancer
Natera NTRA recently announced a partnership with Aveta Biomics to support AVTA 30-01, a global Phase 3 registrational trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results